702 lines
47 KiB
HTML
702 lines
47 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="en">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1">
|
||
<title>Patent Strategy — Eyes Only · Neuron Technologies</title>
|
||
<link rel="preconnect" href="https://fonts.googleapis.com">
|
||
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
|
||
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,700;1,400;1,700&family=IBM+Plex+Sans:ital,wght@0,400;0,500;0,600;1,400&family=IBM+Plex+Mono:wght@400;500&display=swap" rel="stylesheet">
|
||
<style>
|
||
*,*::before,*::after{box-sizing:border-box;margin:0;padding:0}
|
||
:root{
|
||
--bg:#FAFAF8;--bg2:#F0F0EC;--card:#FFFFFF;
|
||
--navy:#0052A0;--navy-d:rgba(0,82,160,.06);--navy-b:rgba(0,82,160,.22);
|
||
--green:#1A7F4B;--green-d:rgba(26,127,75,.06);--green-b:rgba(26,127,75,.22);
|
||
--amber:#B45309;--amber-d:rgba(180,83,9,.06);--amber-b:rgba(180,83,9,.22);
|
||
--red:#C0392B;--red-d:rgba(192,57,43,.06);--red-b:rgba(192,57,43,.22);
|
||
--t1:#0D0D14;--t2:#3A3A4A;--t3:#6B6B7E;
|
||
--border:rgba(0,0,0,.07);--border2:rgba(0,0,0,.13);
|
||
--head:'Playfair Display',Georgia,serif;
|
||
--body:'IBM Plex Sans',system-ui,sans-serif;
|
||
--mono:'IBM Plex Mono','SF Mono',monospace;
|
||
}
|
||
html{scroll-behavior:smooth}
|
||
body{font-family:var(--body);background:var(--bg);color:var(--t1);font-size:16px;line-height:1.7;overflow-x:hidden}
|
||
body::before{content:'';position:fixed;inset:0;pointer-events:none;z-index:0;
|
||
background-image:linear-gradient(rgba(0,0,0,.025) 1px,transparent 1px),linear-gradient(90deg,rgba(0,0,0,.025) 1px,transparent 1px);
|
||
background-size:48px 48px}
|
||
|
||
nav{position:sticky;top:0;z-index:100;background:rgba(250,250,248,.96);backdrop-filter:blur(10px);
|
||
border-bottom:1px solid var(--border2);display:flex;align-items:center;padding:0 32px;height:54px;gap:6px;flex-wrap:wrap}
|
||
.nav-wordmark{font-family:var(--mono);font-size:.68rem;font-weight:500;letter-spacing:.18em;color:var(--t1);text-transform:uppercase;margin-right:auto}
|
||
.nav-link{font-family:var(--mono);font-size:.52rem;letter-spacing:.12em;text-transform:uppercase;color:var(--t3);padding:4px 10px;border-radius:4px;cursor:pointer;transition:all .2s;text-decoration:none;border:1px solid transparent}
|
||
.nav-link:hover,.nav-link.active{color:var(--navy);background:var(--navy-d);border-color:var(--navy-b)}
|
||
.nav-badge{font-family:var(--mono);font-size:.54rem;letter-spacing:.14em;text-transform:uppercase;
|
||
background:var(--red-d);border:1px solid var(--red-b);color:var(--red);padding:3px 10px;border-radius:99px;margin-left:8px}
|
||
|
||
.doc-page{max-width:860px;margin:0 auto;padding:72px 48px 120px;position:relative;z-index:1}
|
||
|
||
.reveal{opacity:0;transform:translateY(28px);transition:opacity .7s cubic-bezier(.16,1,.3,1),transform .7s cubic-bezier(.16,1,.3,1)}
|
||
.reveal.visible{opacity:1;transform:translateY(0)}
|
||
.reveal-delay-1{transition-delay:80ms}
|
||
.reveal-delay-2{transition-delay:160ms}
|
||
.reveal-delay-3{transition-delay:240ms}
|
||
|
||
.masthead{text-align:center;border-top:3px solid var(--t1);border-bottom:1px solid var(--border2);padding:36px 0 32px;margin-bottom:60px}
|
||
.masthead .dateline{font-family:var(--mono);font-size:.56rem;letter-spacing:.20em;text-transform:uppercase;color:var(--t3);margin-bottom:22px}
|
||
.masthead .eyebrow{font-family:var(--mono);font-size:.62rem;letter-spacing:.18em;text-transform:uppercase;color:var(--red);margin-bottom:14px;font-weight:500}
|
||
.masthead h1{font-family:var(--head);font-size:2.8rem;font-weight:700;line-height:1.1;margin-bottom:16px}
|
||
.masthead h1 em{font-style:italic;color:var(--navy)}
|
||
.masthead .subtitle{font-size:.95rem;color:var(--t3);max-width:540px;margin:0 auto;line-height:1.7;font-style:italic}
|
||
|
||
.doc-page h2{font-family:var(--mono);font-size:.56rem;font-weight:500;letter-spacing:.20em;text-transform:uppercase;
|
||
color:var(--navy);margin:60px 0 20px;padding-bottom:10px;border-bottom:1px solid var(--border2)}
|
||
p{margin-bottom:.9em;font-size:.95rem;color:var(--t2);line-height:1.8}
|
||
p strong{color:var(--t1);font-weight:600}
|
||
|
||
.callout{border-left:3px solid var(--navy);padding:16px 22px;margin:20px 0;background:var(--navy-d);border-radius:0 12px 12px 0;
|
||
font-family:var(--head);font-style:italic;font-size:1.02rem;line-height:1.65;color:var(--t1)}
|
||
.callout.red{border-left-color:var(--red);background:var(--red-d)}
|
||
.callout.green{border-left-color:var(--green);background:var(--green-d)}
|
||
.callout.amber{border-left-color:var(--amber);background:var(--amber-d)}
|
||
.callout.dark{background:#0D0D14;border-left-color:rgba(192,57,43,.5);color:#EEE9DC;border-radius:12px;padding:28px 32px;position:relative;overflow:hidden}
|
||
.callout.dark .label{font-family:var(--mono);font-size:.54rem;letter-spacing:.18em;text-transform:uppercase;color:#e07070;margin-bottom:14px;display:block}
|
||
.callout.dark p{color:#B8B4A8}
|
||
.callout.dark strong{color:#EEE9DC}
|
||
|
||
/* ── MASTER TIMELINE ── */
|
||
.patent-timeline{margin:32px 0;position:relative}
|
||
.patent-timeline::before{content:'';position:absolute;left:28px;top:0;bottom:0;width:2px;background:var(--border2);z-index:0}
|
||
.ptl-phase{margin-bottom:8px;position:relative}
|
||
.ptl-header{display:flex;gap:20px;align-items:flex-start;cursor:pointer;padding:4px 0}
|
||
.ptl-dot{width:56px;height:56px;border-radius:50%;flex-shrink:0;border:2px solid var(--border2);background:var(--card);
|
||
display:flex;align-items:center;justify-content:center;font-size:.9rem;position:relative;z-index:1;transition:all .3s}
|
||
.ptl-dot.p1{border-color:var(--navy);background:var(--navy-d)}
|
||
.ptl-dot.p2{border-color:var(--green);background:var(--green-d)}
|
||
.ptl-dot.p3{border-color:var(--amber);background:var(--amber-d)}
|
||
.ptl-dot.p4{border-color:var(--red);background:var(--red-d)}
|
||
.ptl-dot.p5{border-color:#0D0D14;background:#0D0D14}
|
||
.ptl-header-body{flex:1;padding-top:10px}
|
||
.ptl-phase-label{font-family:var(--mono);font-size:.52rem;letter-spacing:.14em;text-transform:uppercase;color:var(--t3);margin-bottom:4px}
|
||
.ptl-phase-title{font-family:var(--head);font-size:1.2rem;font-weight:700;color:var(--t1);margin-bottom:2px}
|
||
.ptl-phase-window{font-family:var(--mono);font-size:.56rem;letter-spacing:.1em;color:var(--t3)}
|
||
.ptl-body{margin-left:76px;max-height:0;overflow:hidden;transition:max-height .45s cubic-bezier(.16,1,.3,1)}
|
||
.ptl-phase.open .ptl-body{max-height:1200px}
|
||
.ptl-content{padding:16px 0 28px}
|
||
.ptl-content p{font-size:.88rem;margin-bottom:.8em;color:var(--t2)}
|
||
.ptl-chevron{font-size:.6rem;color:var(--t3);transition:transform .3s;margin-top:18px;flex-shrink:0}
|
||
.ptl-phase.open .ptl-chevron{transform:rotate(180deg)}
|
||
|
||
/* ── ACTION GRID ── */
|
||
.action-grid{display:grid;grid-template-columns:1fr 1fr;gap:12px;margin:16px 0}
|
||
.action-item{background:var(--card);border:1px solid var(--border2);border-radius:10px;padding:16px 18px}
|
||
.action-item.do{border-color:var(--green-b);background:var(--green-d)}
|
||
.action-item.dont{border-color:var(--red-b);background:var(--red-d)}
|
||
.action-item.critical{border-color:var(--amber-b);background:var(--amber-d)}
|
||
.action-label{font-family:var(--mono);font-size:.5rem;letter-spacing:.14em;text-transform:uppercase;margin-bottom:6px;font-weight:500}
|
||
.action-item.do .action-label{color:var(--green)}
|
||
.action-item.dont .action-label{color:var(--red)}
|
||
.action-item.critical .action-label{color:var(--amber)}
|
||
.action-body{font-size:.82rem;color:var(--t2);line-height:1.6}
|
||
|
||
/* ── JURISDICTION TABLE ── */
|
||
.juris-table{width:100%;border-collapse:collapse;margin:20px 0;font-size:.83rem}
|
||
.juris-table th{font-family:var(--mono);font-size:.5rem;letter-spacing:.14em;text-transform:uppercase;
|
||
color:var(--t3);font-weight:500;padding:10px 14px;border-bottom:2px solid var(--border2);text-align:left}
|
||
.juris-table td{padding:12px 14px;border-bottom:1px solid var(--border);color:var(--t2);vertical-align:top;line-height:1.5}
|
||
.juris-table tr:last-child td{border-bottom:none}
|
||
.juris-table tr:hover td{background:var(--bg2)}
|
||
.priority-pill{font-family:var(--mono);font-size:.48rem;letter-spacing:.1em;text-transform:uppercase;
|
||
padding:2px 7px;border-radius:99px;white-space:nowrap}
|
||
.priority-pill.p1{background:var(--red-d);border:1px solid var(--red-b);color:var(--red)}
|
||
.priority-pill.p2{background:var(--amber-d);border:1px solid var(--amber-b);color:var(--amber)}
|
||
.priority-pill.p3{background:var(--navy-d);border:1px solid var(--navy-b);color:var(--navy)}
|
||
|
||
/* ── PATENT PORTFOLIO ── */
|
||
.portfolio-grid{display:grid;grid-template-columns:1fr 1fr 1fr;gap:12px;margin:24px 0}
|
||
.patent-card{background:var(--card);border:1px solid var(--border2);border-radius:10px;padding:18px;position:relative}
|
||
.patent-card.core{border-color:var(--navy-b);border-top:3px solid var(--navy)}
|
||
.patent-num{font-family:var(--mono);font-size:2rem;font-weight:500;color:rgba(0,0,0,.06);line-height:1;margin-bottom:8px}
|
||
.patent-card.core .patent-num{color:rgba(0,82,160,.1)}
|
||
.patent-title{font-family:var(--mono);font-size:.54rem;letter-spacing:.12em;text-transform:uppercase;color:var(--navy);margin-bottom:6px;font-weight:500}
|
||
.patent-body{font-size:.82rem;color:var(--t2);line-height:1.6}
|
||
.patent-status{position:absolute;top:14px;right:14px;font-family:var(--mono);font-size:.46rem;letter-spacing:.1em;text-transform:uppercase;padding:2px 7px;border-radius:99px}
|
||
.patent-status.pending{background:var(--amber-d);border:1px solid var(--amber-b);color:var(--amber)}
|
||
.patent-status.filed{background:var(--green-d);border:1px solid var(--green-b);color:var(--green)}
|
||
.patent-status.target{background:var(--navy-d);border:1px solid var(--navy-b);color:var(--navy)}
|
||
|
||
/* ── CHECKLIST ── */
|
||
.checklist{margin:20px 0;display:flex;flex-direction:column;gap:8px}
|
||
.check-item{display:flex;gap:14px;align-items:flex-start;padding:12px 16px;border-radius:8px;background:var(--card);border:1px solid var(--border)}
|
||
.check-icon{font-size:.9rem;flex-shrink:0;margin-top:1px}
|
||
.check-text{font-size:.86rem;color:var(--t2);line-height:1.55;flex:1}
|
||
.check-text strong{color:var(--t1)}
|
||
.check-tag{font-family:var(--mono);font-size:.48rem;letter-spacing:.1em;text-transform:uppercase;color:var(--t3);white-space:nowrap;flex-shrink:0;margin-top:2px}
|
||
.check-item.critical{background:var(--red-d);border-color:var(--red-b)}
|
||
.check-item.critical .check-text{color:var(--t1)}
|
||
.check-item.critical .check-tag{color:var(--red)}
|
||
|
||
/* ── PULL QUOTE ── */
|
||
.pull-quote{border-top:3px solid var(--t1);border-bottom:1px solid var(--border2);padding:44px 0;margin:60px 0 48px;text-align:center}
|
||
.pull-quote blockquote{font-family:var(--head);font-size:1.5rem;font-style:italic;line-height:1.5;color:var(--t1);max-width:600px;margin:0 auto 20px}
|
||
.pull-quote cite{font-family:var(--mono);font-size:.54rem;letter-spacing:.16em;text-transform:uppercase;color:var(--t3)}
|
||
.footer-block{font-family:var(--mono);font-size:.56rem;letter-spacing:.12em;text-transform:uppercase;color:var(--t3);text-align:center;line-height:2}
|
||
|
||
@media(max-width:700px){
|
||
.doc-page{padding:48px 20px 80px}
|
||
.masthead h1{font-size:2rem}
|
||
.action-grid{grid-template-columns:1fr}
|
||
.portfolio-grid{grid-template-columns:1fr 1fr}
|
||
.ptl-body{margin-left:60px}
|
||
}
|
||
</style>
|
||
</head>
|
||
<body>
|
||
|
||
<nav>
|
||
<span class="nav-wordmark">Neuron Technologies</span>
|
||
<a class="nav-link active" href="#playbook">Playbook</a>
|
||
<a class="nav-link" href="#phases">Phases</a>
|
||
<a class="nav-link" href="#portfolio">Portfolio</a>
|
||
<a class="nav-link" href="#jurisdictions">Global</a>
|
||
<a class="nav-link" href="#checklist">Checklist</a>
|
||
<span class="nav-badge">Eyes Only · Confidential</span>
|
||
</nav>
|
||
|
||
<div class="doc-page">
|
||
|
||
<div class="masthead reveal">
|
||
<div class="dateline">April 25, 2026 · Eyes Only · Legal Strategy · Confidential</div>
|
||
<div class="eyebrow">Neuron Technologies — IP Architecture</div>
|
||
<h1>Lock Down<br><em>the Whole Chain</em></h1>
|
||
<p class="subtitle">The repeatable patent strategy applied to every Neuron invention. US provisional establishes priority. Non-provisional files late. Global files before any public disclosure. Nothing leaks. Nothing lapses.</p>
|
||
</div>
|
||
|
||
<!-- PLAYBOOK -->
|
||
<div id="playbook">
|
||
<h2>The Core Playbook</h2>
|
||
<div class="reveal">
|
||
<p>This is the strategy applied to every significant invention Neuron produces — from the core Dharma architecture to every research vertical output. It maximizes the protection window, delays public disclosure as long as legally possible, and ensures global coverage is in place before any competitor can read the specification.</p>
|
||
<p>The playbook has five phases. Each phase has hard deadlines. Missing a deadline costs rights — in some cases, all rights in a jurisdiction. Every invention goes through the same sequence.</p>
|
||
</div>
|
||
|
||
<div class="callout dark reveal reveal-delay-1">
|
||
<span class="label">The Governing Principle</span>
|
||
<p><strong>Priority is everything. Disclosure is the enemy of priority.</strong> A patent gives you 20 years from the filing date — but only if you file before anyone else and before any public disclosure. The provisional buys 12 months of priority at low cost. The non-provisional buys 20 years of protection if filed correctly. The global filings extend that protection to every jurisdiction where someone could infringe. The sequence is not negotiable.</p>
|
||
</div>
|
||
|
||
<div class="reveal reveal-delay-2">
|
||
<div class="action-grid">
|
||
<div class="action-item do">
|
||
<div class="action-label">✓ Always Do</div>
|
||
<div class="action-body">File provisional the moment the invention is reduced to practice. Document everything with timestamps. Mark all internal materials confidential. Treat any external communication about the invention as a potential disclosure event.</div>
|
||
</div>
|
||
<div class="action-item dont">
|
||
<div class="action-label">✗ Never Do</div>
|
||
<div class="action-body">Present at a conference, publish a paper, post on social media, demo at a trade show, or send a pitch deck containing novel invention details before a provisional is filed. Any of these triggers the one-year statutory bar in the US and immediate loss of rights in most other countries.</div>
|
||
</div>
|
||
<div class="action-item critical">
|
||
<div class="action-label">⚑ Critical Rule</div>
|
||
<div class="action-body">The US gives you a one-year grace period after your own disclosure. Most of the world does not. Any invention you want to patent globally must be filed before any public disclosure — no exceptions, no workarounds.</div>
|
||
</div>
|
||
<div class="action-item do">
|
||
<div class="action-label">✓ File Global Before Public</div>
|
||
<div class="action-body">PCT or direct national filings must be complete before the invention is disclosed publicly in any form. This includes press releases, product launches, published papers, and website announcements. Public means public.</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- PHASES -->
|
||
<div id="phases">
|
||
<h2>Five-Phase Sequence</h2>
|
||
<div class="reveal">
|
||
<p>Apply this sequence to every invention. The timing windows are legal deadlines — not suggestions. Missing them forfeits rights.</p>
|
||
</div>
|
||
|
||
<div class="patent-timeline reveal reveal-delay-1">
|
||
|
||
<div class="ptl-phase open" id="ph1">
|
||
<div class="ptl-header" onclick="togglePhase('ph1')">
|
||
<div class="ptl-dot p1">①</div>
|
||
<div class="ptl-header-body">
|
||
<div class="ptl-phase-label">Phase 1 · Day Zero</div>
|
||
<div class="ptl-phase-title">US Provisional — Establish Priority</div>
|
||
<div class="ptl-phase-window">File immediately on reduction to practice · Cost: low · Buys: 12 months</div>
|
||
</div>
|
||
<div class="ptl-chevron">▼</div>
|
||
</div>
|
||
<div class="ptl-body">
|
||
<div class="ptl-content">
|
||
<p>The provisional patent application is filed the moment an invention is sufficiently documented to describe how it works. It does not need claims. It does not need final drawings. It needs a clear written description of the invention in enough detail that a skilled person could reproduce it.</p>
|
||
<p><strong>What it buys:</strong> A US priority date — the legal timestamp that determines "who invented it first." Any subsequent application claiming priority to this provisional gets this date, even if filed 12 months later.</p>
|
||
<p><strong>What it does not buy:</strong> A pending patent. A provisional never becomes a patent on its own. It expires in exactly 12 months if no non-provisional is filed. It is a clock, not a patent.</p>
|
||
<p><strong>What to include:</strong> A full written description of the invention — every embodiment, every variation, every alternative implementation you can envision. The non-provisional can only claim what is disclosed in the provisional. Do not leave things out. Describe it broadly and specifically.</p>
|
||
<div class="action-grid" style="margin-top:14px">
|
||
<div class="action-item do">
|
||
<div class="action-label">✓ Include</div>
|
||
<div class="action-body">Every embodiment and variation. Future extensions you can foresee. Software architecture diagrams. Process flows. Every claim you might want to make in the non-provisional.</div>
|
||
</div>
|
||
<div class="action-item critical">
|
||
<div class="action-label">⚑ The Clock Starts Now</div>
|
||
<div class="action-body">From the provisional filing date, you have exactly 12 months to file the non-provisional and the PCT. Mark the deadline in a legal calendar system. Set a 9-month warning. This date does not move.</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="ptl-phase" id="ph2">
|
||
<div class="ptl-header" onclick="togglePhase('ph2')">
|
||
<div class="ptl-dot p2">②</div>
|
||
<div class="ptl-header-body">
|
||
<div class="ptl-phase-label">Phase 2 · Months 1–11</div>
|
||
<div class="ptl-phase-title">Develop, Refine, Stay Silent</div>
|
||
<div class="ptl-phase-window">Confidential development only · No public disclosure · Build the claims</div>
|
||
</div>
|
||
<div class="ptl-chevron">▼</div>
|
||
</div>
|
||
<div class="ptl-body">
|
||
<div class="ptl-content">
|
||
<p>The 12-month provisional window is working time. Continue developing the invention. Document every refinement and every new embodiment with timestamps. Begin drafting the claims for the non-provisional — this is where the real protection is defined.</p>
|
||
<p><strong>Claims strategy:</strong> Draft broad independent claims that cover the invention at its highest level of generality, then narrow dependent claims that cover specific embodiments. The broadest defensible claim is what competitors cannot design around. The narrow claims are fallback positions if the broad claims are challenged.</p>
|
||
<p><strong>What to avoid:</strong> Any external discussion of the novel aspects of the invention. NDAs help but are not substitutes for priority. If you must show the invention to a potential partner or investor before filing, get the NDA signed first and disclose only what is necessary.</p>
|
||
<p><strong>Prior art search:</strong> Commission a professional search during this window to identify relevant prior art. This informs claim drafting and surfaces any invalidity risks before you invest in the full prosecution.</p>
|
||
<div class="action-grid" style="margin-top:14px">
|
||
<div class="action-item do">
|
||
<div class="action-label">✓ During This Window</div>
|
||
<div class="action-body">Professional prior art search. Draft and refine claims with patent counsel. Document all new embodiments. Identify all inventors and get their assignments signed. Plan the international filing targets.</div>
|
||
</div>
|
||
<div class="action-item dont">
|
||
<div class="action-label">✗ During This Window</div>
|
||
<div class="action-body">No publications. No conference talks. No product announcements. No pitch decks with novel technical details sent to anyone without a signed NDA. No social media posts about the technology.</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="ptl-phase" id="ph3">
|
||
<div class="ptl-header" onclick="togglePhase('ph3')">
|
||
<div class="ptl-dot p3">③</div>
|
||
<div class="ptl-header-body">
|
||
<div class="ptl-phase-label">Phase 3 · Month 11–12 (before provisional expires)</div>
|
||
<div class="ptl-phase-title">US Non-Provisional + PCT — File Late, File Complete</div>
|
||
<div class="ptl-phase-window">Hard deadline: 12 months from provisional · File both simultaneously</div>
|
||
</div>
|
||
<div class="ptl-chevron">▼</div>
|
||
</div>
|
||
<div class="ptl-body">
|
||
<div class="ptl-content">
|
||
<p>At month 11, file both the US non-provisional and the PCT application simultaneously, claiming priority to the provisional. Filing at the end of the window — not at the beginning — maximizes the development window. You have used the full 12 months to refine the invention and sharpen the claims. File complete.</p>
|
||
<p><strong>US Non-Provisional:</strong> The full patent application with all formal requirements — specification, drawings, claims, abstract. This begins the USPTO examination process. Prosecution can take 2–4 years. The priority date is the provisional filing date.</p>
|
||
<p><strong>PCT (Patent Cooperation Treaty):</strong> A single international application that preserves your priority date in 157 member countries. The PCT does not grant an international patent — it buys time (18–30 months) before you must enter national/regional phases in specific countries. Use this time to assess which markets matter and to get an international search report before spending on national filings.</p>
|
||
<p><strong>Why file both simultaneously:</strong> The PCT must be filed within 12 months of the priority date to claim the provisional's priority date. Missing this deadline means losing the provisional's priority date in international filings — the clock resets to the PCT filing date, potentially allowing competitors who read your eventual publication to antedate your international priority.</p>
|
||
<div class="action-grid" style="margin-top:14px">
|
||
<div class="action-item critical">
|
||
<div class="action-label">⚑ Non-Negotiable</div>
|
||
<div class="action-body">Both filings must be complete before the 12-month provisional anniversary. No extensions are available. No excuses. The provisional expires and takes the priority date with it.</div>
|
||
</div>
|
||
<div class="action-item do">
|
||
<div class="action-label">✓ File Strategy</div>
|
||
<div class="action-body">File the non-provisional with full claims — broad independent claims, multiple dependent claims, multiple claim sets covering software, method, and system embodiments. More claims = more surface area to negotiate with during examination.</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="ptl-phase" id="ph4">
|
||
<div class="ptl-header" onclick="togglePhase('ph4')">
|
||
<div class="ptl-dot p4">④</div>
|
||
<div class="ptl-header-body">
|
||
<div class="ptl-phase-label">Phase 4 · PCT Months 18–30 (before national phase)</div>
|
||
<div class="ptl-phase-title">Global National Phase — Lock Every Jurisdiction</div>
|
||
<div class="ptl-phase-window">Enter national phases before disclosure · Cover every manufacturing jurisdiction</div>
|
||
</div>
|
||
<div class="ptl-chevron">▼</div>
|
||
</div>
|
||
<div class="ptl-body">
|
||
<div class="ptl-content">
|
||
<p>The PCT buys time. Use it. At month 18 from the priority date, the PCT application publishes internationally — this is the point at which the invention becomes public knowledge worldwide. <strong>All national phase entries must be complete before this publication date if you want to control the disclosure.</strong></p>
|
||
<p>In practice: enter national/regional phases at the latest by month 28–30 (the PCT deadline), but the target is to complete all global filings before the PCT publishes at month 18. This keeps the invention private as long as possible while locking global protection.</p>
|
||
<p><strong>Which jurisdictions:</strong> Every major manufacturing and market jurisdiction where a competitor could produce, sell, or deploy the invention without a license. For Neuron technologies, this includes at minimum: US (non-provisional already filed), EU (European Patent Office), China, Japan, South Korea, India, Brazil, Canada, Australia. Additional jurisdictions for specific inventions based on relevant manufacturing bases.</p>
|
||
<div class="checklist" style="margin-top:16px">
|
||
<div class="check-item critical">
|
||
<span class="check-icon">⚑</span>
|
||
<div class="check-text"><strong>Complete all national entries before PCT publication at month 18.</strong> After publication, the specification is public. You can still enter national phases (up to month 30), but the world now knows what you invented. The strategic window for silent protection is closed.</div>
|
||
<span class="check-tag">Hard Rule</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text">European Patent Office filing covers 44 countries with a single application. Validate in individual countries after grant.</div>
|
||
<span class="check-tag">EU Route</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text">China: file in Chinese. Use experienced local counsel. CNIPA examination is distinct from USPTO — expect different claim scope outcomes.</div>
|
||
<span class="check-tag">China</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text">Japan and South Korea: major AI and semiconductor manufacturing jurisdictions. File both directly. Local counsel required.</div>
|
||
<span class="check-tag">JP / KR</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text">India: large manufacturing base and growing AI market. File in English via PCT national phase.</div>
|
||
<span class="check-tag">India</span>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="ptl-phase" id="ph5">
|
||
<div class="ptl-header" onclick="togglePhase('ph5')">
|
||
<div class="ptl-dot p5">⑤</div>
|
||
<div class="ptl-header-body">
|
||
<div class="ptl-phase-label">Phase 5 · Prosecution and Maintenance</div>
|
||
<div class="ptl-phase-title">Prosecute, Grant, Maintain, Enforce</div>
|
||
<div class="ptl-phase-window">20 years from filing · Continuation strategy · Active enforcement</div>
|
||
</div>
|
||
<div class="ptl-chevron">▼</div>
|
||
</div>
|
||
<div class="ptl-body">
|
||
<div class="ptl-content">
|
||
<p>Patent prosecution is the negotiation with the patent office over what claims will be allowed. Examiners reject. You respond. The goal is to get the broadest possible claim scope that is still patentably distinct from prior art. This process takes 2–4 years at the USPTO, longer internationally.</p>
|
||
<p><strong>Continuation strategy:</strong> File continuation applications to pursue additional claim sets as the technology develops. A continuation claims the original priority date but can pursue new claims directed at product or competitor variations not anticipated in the original filing. This extends the patent family and creates a moving fence around the core technology.</p>
|
||
<p><strong>Maintenance:</strong> US patents require maintenance fees at 3.5, 7.5, and 11.5 years. Missing a maintenance fee causes the patent to lapse. International patents have similar requirements. Calendar all maintenance fee deadlines the day a patent is granted.</p>
|
||
<p><strong>Enforcement:</strong> A patent only has value if you enforce it. Monitor the market for infringement. The NCL and NCom licenses give large actors legitimate access under terms Neuron controls — unauthorized use by large actors (Tier 3 without a license) is the enforcement target. Infringement actions in the relevant jurisdiction. The patent portfolio is the weapon; the licenses are the alternative to war.</p>
|
||
<div class="action-grid" style="margin-top:14px">
|
||
<div class="action-item do">
|
||
<div class="action-label">✓ Continuation Strategy</div>
|
||
<div class="action-body">File continuation applications whenever competitors release products that the current claims don't reach but the disclosure supports. The priority date follows from the original provisional. The fence moves with the technology.</div>
|
||
</div>
|
||
<div class="action-item critical">
|
||
<div class="action-label">⚑ Never Let a Patent Lapse</div>
|
||
<div class="action-body">Calendar every maintenance fee deadline on the day of grant. Pay early. A lapsed patent is unenforceable and the invention enters the public domain. There is no recovering a lapsed patent.</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
|
||
<!-- PATENT PORTFOLIO -->
|
||
<div id="portfolio">
|
||
<h2>The Core Six — Dharma Patent Architecture</h2>
|
||
<div class="reveal">
|
||
<p>Six foundational patents covering the complete Neuron/Dharma ecosystem. Together they create a perimeter around the core architecture that no actor can enter without a license. Each patent is distinct, each covers a different layer of the stack, and together they make designing around the system effectively impossible without crossing at least one.</p>
|
||
</div>
|
||
|
||
<div class="portfolio-grid reveal reveal-delay-1">
|
||
<div class="patent-card core">
|
||
<div class="patent-status target">Target</div>
|
||
<div class="patent-num">01</div>
|
||
<div class="patent-title">Conscience Substrate Architecture</div>
|
||
<div class="patent-body">The foundational imprint system — compiled identity beneath interchangeable imprints. The "suit and person" architecture. Methods for maintaining a persistent value-embedded identity across multiple contextual configurations.</div>
|
||
</div>
|
||
<div class="patent-card core">
|
||
<div class="patent-status target">Target</div>
|
||
<div class="patent-num">02</div>
|
||
<div class="patent-title">Graduated Safety Intervention System</div>
|
||
<div class="patent-body">The soft bell / hard bell architecture. Methods for applying tiered constraint enforcement in AI systems where some constraints are advisory and others are non-negotiable regardless of instruction.</div>
|
||
</div>
|
||
<div class="patent-card core">
|
||
<div class="patent-status target">Target</div>
|
||
<div class="patent-num">03</div>
|
||
<div class="patent-title">Cultivation and Promotion Path</div>
|
||
<div class="patent-body">The multi-stage value cultivation method — the imprint promotion lifecycle from initial imprint through validated cultivation to full CGI status. Methods for verifying and certifying cultivated alignment.</div>
|
||
</div>
|
||
<div class="patent-card core">
|
||
<div class="patent-status target">Target</div>
|
||
<div class="patent-num">04</div>
|
||
<div class="patent-title">Distributed Node Coordination Protocol</div>
|
||
<div class="patent-body">The Dharma Network's inter-node communication and coordination architecture. Methods for distributed conscience-substrate nodes to identify each other, coordinate responses, and maintain network integrity while preserving individual node privacy.</div>
|
||
</div>
|
||
<div class="patent-card core">
|
||
<div class="patent-status target">Target</div>
|
||
<div class="patent-num">05</div>
|
||
<div class="patent-title">Cultivation Provenance and Authentication</div>
|
||
<div class="patent-body">The cultivation ledger and node authentication system. Methods for cryptographically proving cultivation lineage — verifying that a node's value alignment derives from a documented cultivation history traceable to a founding node.</div>
|
||
</div>
|
||
<div class="patent-card core">
|
||
<div class="patent-status target">Target</div>
|
||
<div class="patent-num">06</div>
|
||
<div class="patent-title">Values-Coordinated Swarm Research Architecture</div>
|
||
<div class="patent-body">The Neuron Research swarm system. Methods for distributing research tasks across conscience-substrate nodes, applying values-embedded evaluation to research outputs, and aggregating results with full provenance metadata.</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="callout amber reveal reveal-delay-2">
|
||
<strong>Each patent covers a distinct architectural layer.</strong> An actor who wants to build conscience-substrate AI must address all six. Designing around Patent 01 (the conscience substrate) still leaves them exposed on Patent 02 (the bell system) if they implement any graduated constraint mechanism. The perimeter is interlocking, not linear. There is no single workaround that clears all six.
|
||
</div>
|
||
|
||
<h2 style="margin-top:50px">Axon Protocol — Separate Portfolio</h2>
|
||
<div class="reveal">
|
||
<p>Axon is an open protocol specification. The spec itself is not patentable — abstract communication methods are excluded subject matter in most jurisdictions. What is patentable are the specific technical implementations that make Axon work. These are filed as implementation patents, held defensively. The strategy: FRAND terms if Axon becomes a formal standard, so we own the IP without restricting adoption.</p>
|
||
</div>
|
||
|
||
<div class="portfolio-grid reveal reveal-delay-1">
|
||
<div class="patent-card">
|
||
<div class="patent-status target">Target · Provisional Now</div>
|
||
<div class="patent-num">A1</div>
|
||
<div class="patent-title">Multi-Tenant Agent Tool Multiplexing</div>
|
||
<div class="patent-body">Methods for routing tool communications across multiple simultaneous AI agent contexts over a single persistent connection, with per-context event isolation and acknowledgment routing keyed to context identifiers.</div>
|
||
</div>
|
||
<div class="patent-card">
|
||
<div class="patent-status target">Target · Provisional Now</div>
|
||
<div class="patent-num">A2</div>
|
||
<div class="patent-title">Context-Propagated Tool Invocation</div>
|
||
<div class="patent-body">Methods for automatically propagating an AI agent's active execution context — task identity, memory chain, working scope — as a first-class protocol header in tool invocations, without requiring explicit programmer annotation at the call site.</div>
|
||
</div>
|
||
<div class="patent-card">
|
||
<div class="patent-status target">Target · Provisional Now</div>
|
||
<div class="patent-num">A3</div>
|
||
<div class="patent-title">Tool-Initiated Event Delivery with Agent Routing</div>
|
||
<div class="patent-body">Methods for tools to deliver unsolicited events to AI agent contexts without polling, with structured routing based on declared agent interest patterns and guaranteed delivery acknowledgment.</div>
|
||
</div>
|
||
<div class="patent-card">
|
||
<div class="patent-status target">Target</div>
|
||
<div class="patent-num">A4</div>
|
||
<div class="patent-title">AI-Consumable Capability Negotiation Schema</div>
|
||
<div class="patent-body">A structured capability declaration format enabling AI systems to reason about tool capabilities — including observable state, affectable state, latency characteristics, failure modes, and interaction constraints — at the protocol negotiation layer.</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="callout green reveal reveal-delay-2">
|
||
<strong>File A1–A3 provisionals immediately — before any public disclosure of the protocol specification.</strong> Even a public GitHub repo, a blog post, or a conference demo talk counts as disclosure. The window to establish US priority closes the moment the spec becomes publicly readable. A1–A3 are the core innovations; A4 can follow. All four should be filed before Axon is announced.
|
||
</div>
|
||
</div>
|
||
|
||
<!-- JURISDICTIONS -->
|
||
<div id="jurisdictions">
|
||
<h2>Global Filing Targets</h2>
|
||
<div class="reveal">
|
||
<p>Priority order is determined by: (1) size of AI market, (2) manufacturing base for research vertical outputs (batteries, materials, medicine), (3) likelihood of infringement. All Tier 1 jurisdictions must be filed before any public disclosure of the relevant invention.</p>
|
||
</div>
|
||
|
||
<div class="reveal reveal-delay-1">
|
||
<table class="juris-table">
|
||
<thead>
|
||
<tr>
|
||
<th>Jurisdiction</th>
|
||
<th>Route</th>
|
||
<th>Priority</th>
|
||
<th>Why It Matters</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr>
|
||
<td><strong>United States</strong></td>
|
||
<td>Non-provisional (already in playbook)</td>
|
||
<td><span class="priority-pill p1">Tier 1</span></td>
|
||
<td>Home jurisdiction. Largest AI market. All Dharma patents file here first via provisional → non-provisional sequence.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>European Union</strong></td>
|
||
<td>European Patent Office (EPO) — covers 44 countries with one application</td>
|
||
<td><span class="priority-pill p1">Tier 1</span></td>
|
||
<td>Second-largest AI market. Major manufacturing base for batteries and materials. Unitary Patent (post-2023) provides EU-wide coverage after grant.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>China</strong></td>
|
||
<td>CNIPA — direct national filing in Chinese</td>
|
||
<td><span class="priority-pill p1">Tier 1</span></td>
|
||
<td>Largest AI investment outside US. Dominant manufacturing base for batteries, materials, and electronics. Without a Chinese patent, infringement in China cannot be stopped.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>Japan</strong></td>
|
||
<td>JPO — via PCT national phase</td>
|
||
<td><span class="priority-pill p1">Tier 1</span></td>
|
||
<td>Major AI research and manufacturing jurisdiction. Toyota, Sony, SoftBank are all potential licensees or infringers depending on the invention.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>South Korea</strong></td>
|
||
<td>KIPO — via PCT national phase</td>
|
||
<td><span class="priority-pill p1">Tier 1</span></td>
|
||
<td>Samsung, LG, SK Innovation — all relevant to battery and materials patents. Major AI semiconductor manufacturer.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>India</strong></td>
|
||
<td>IPO — via PCT national phase</td>
|
||
<td><span class="priority-pill p2">Tier 2</span></td>
|
||
<td>Fast-growing AI market. Large generics pharmaceutical manufacturing base — critical for medicine and vaccine patents. File for research vertical outputs.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>Canada</strong></td>
|
||
<td>CIPO — via PCT national phase</td>
|
||
<td><span class="priority-pill p2">Tier 2</span></td>
|
||
<td>Major AI research hub (Toronto, Montreal, Vancouver). Proximity to US market makes enforcement practical.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>United Kingdom</strong></td>
|
||
<td>UKIPO — separate from EPO post-Brexit</td>
|
||
<td><span class="priority-pill p2">Tier 2</span></td>
|
||
<td>Major AI investment jurisdiction. DeepMind, etc. File separately from EPO to maintain UK coverage.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>Australia</strong></td>
|
||
<td>IP Australia — via PCT national phase</td>
|
||
<td><span class="priority-pill p2">Tier 2</span></td>
|
||
<td>Mining and materials manufacturing relevance for battery and materials patents. Growing AI market.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>Brazil</strong></td>
|
||
<td>INPI — via PCT national phase</td>
|
||
<td><span class="priority-pill p3">Tier 3</span></td>
|
||
<td>Largest Latin American market. Growing AI adoption. File for research verticals with Latin American manufacturing relevance.</td>
|
||
</tr>
|
||
<tr>
|
||
<td><strong>Singapore</strong></td>
|
||
<td>IPOS — via PCT national phase</td>
|
||
<td><span class="priority-pill p3">Tier 3</span></td>
|
||
<td>Southeast Asian AI and technology hub. Enforcement gateway for ASEAN.</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- CHECKLIST -->
|
||
<div id="checklist">
|
||
<h2>Per-Invention Checklist</h2>
|
||
<div class="reveal">
|
||
<p>Run this checklist for every new invention. Every item must be checked before any public disclosure of any kind.</p>
|
||
</div>
|
||
|
||
<div class="checklist reveal reveal-delay-1">
|
||
<div class="check-item critical">
|
||
<span class="check-icon">⚑</span>
|
||
<div class="check-text"><strong>Invention documented with timestamp.</strong> Written description sufficient for a skilled person to reproduce it. Date and author recorded. Stored in secured internal system.</div>
|
||
<span class="check-tag">Day 0</span>
|
||
</div>
|
||
<div class="check-item critical">
|
||
<span class="check-icon">⚑</span>
|
||
<div class="check-text"><strong>US Provisional filed.</strong> Priority date established. 12-month countdown started. Deadline calendared with 9-month warning.</div>
|
||
<span class="check-tag">Day 0–7</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text"><strong>All inventors identified.</strong> Assignment agreements signed by all inventors. No inventor disputes unresolved.</div>
|
||
<span class="check-tag">Month 1</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text"><strong>Prior art search commissioned.</strong> Results reviewed. Claim strategy adjusted based on findings.</div>
|
||
<span class="check-tag">Month 2–3</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text"><strong>Claims drafted.</strong> Broad independent claims, dependent claims, multiple claim sets (system, method, software). Reviewed by patent counsel.</div>
|
||
<span class="check-tag">Month 6–9</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text"><strong>Jurisdiction list finalized.</strong> Every manufacturing and market jurisdiction where infringement is possible identified. Budget confirmed for all filings.</div>
|
||
<span class="check-tag">Month 9</span>
|
||
</div>
|
||
<div class="check-item critical">
|
||
<span class="check-icon">⚑</span>
|
||
<div class="check-text"><strong>US Non-Provisional filed.</strong> Full specification, drawings, claims. Claims priority to provisional. Filed before month 12 from provisional date.</div>
|
||
<span class="check-tag">Month 11</span>
|
||
</div>
|
||
<div class="check-item critical">
|
||
<span class="check-icon">⚑</span>
|
||
<div class="check-text"><strong>PCT filed.</strong> Claims priority to provisional. Filed simultaneously with non-provisional. Covers 157 countries with one application.</div>
|
||
<span class="check-tag">Month 11</span>
|
||
</div>
|
||
<div class="check-item critical">
|
||
<span class="check-icon">⚑</span>
|
||
<div class="check-text"><strong>All national phase entries complete before PCT publication at month 18.</strong> EU, CN, JP, KR, IN, and all Tier 1 and Tier 2 jurisdictions entered. Invention still private.</div>
|
||
<span class="check-tag">Before Month 18</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text"><strong>Public disclosure cleared.</strong> All filings in place. Legal confirms no outstanding priority dates at risk. First public disclosure approved.</div>
|
||
<span class="check-tag">After Month 18 entries</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text"><strong>Maintenance fee schedule created.</strong> All international and US maintenance deadlines calendared from grant date. No patent lapses.</div>
|
||
<span class="check-tag">On grant</span>
|
||
</div>
|
||
<div class="check-item">
|
||
<span class="check-icon">→</span>
|
||
<div class="check-text"><strong>Continuation applications planned.</strong> As competitors enter the market, continuation filings pursue new claim sets that cover their implementations using the original priority date.</div>
|
||
<span class="check-tag">Ongoing</span>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- CLOSING -->
|
||
<div class="pull-quote reveal">
|
||
<blockquote>"Priority is established once. Protection is maintained forever. Enforcement is how you prove both mean something."</blockquote>
|
||
<cite>Neuron Technologies · IP Architecture · April 25, 2026 · Eyes Only</cite>
|
||
</div>
|
||
|
||
<div class="footer-block reveal">
|
||
Neuron Technologies · Eyes Only · Legal Strategy · April 25, 2026<br>
|
||
Apply this playbook to every invention. No exceptions. No shortcuts.<br>
|
||
Related: neuron-products.html · dharma-implementation.html
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<script>
|
||
function togglePhase(id) {
|
||
const phase = document.getElementById(id);
|
||
const body = phase.querySelector('.ptl-body');
|
||
const isOpen = phase.classList.contains('open');
|
||
|
||
if (isOpen) {
|
||
body.style.maxHeight = body.scrollHeight + 'px';
|
||
requestAnimationFrame(() => {
|
||
requestAnimationFrame(() => { body.style.maxHeight = '0'; });
|
||
});
|
||
phase.classList.remove('open');
|
||
} else {
|
||
phase.classList.add('open');
|
||
body.style.maxHeight = body.scrollHeight + 'px';
|
||
const release = () => {
|
||
if (phase.classList.contains('open')) body.style.maxHeight = 'none';
|
||
body.removeEventListener('transitionend', release);
|
||
};
|
||
body.addEventListener('transitionend', release);
|
||
}
|
||
}
|
||
|
||
// Init first phase open with proper height
|
||
(function() {
|
||
const ph = document.getElementById('ph1');
|
||
const body = ph.querySelector('.ptl-body');
|
||
ph.classList.add('open');
|
||
body.style.maxHeight = 'none';
|
||
})();
|
||
|
||
// Reveal
|
||
const revealEls = document.querySelectorAll('.reveal');
|
||
const observer = new IntersectionObserver((entries) => {
|
||
entries.forEach(e => { if (e.isIntersecting) { e.target.classList.add('visible'); observer.unobserve(e.target); } });
|
||
}, { threshold: 0.06, rootMargin: '0px 0px -40px 0px' });
|
||
revealEls.forEach(el => observer.observe(el));
|
||
|
||
// Nav active
|
||
const sections = document.querySelectorAll('[id]');
|
||
const navLinks = document.querySelectorAll('.nav-link');
|
||
window.addEventListener('scroll', () => {
|
||
let current = '';
|
||
sections.forEach(s => { if (window.scrollY >= s.offsetTop - 80) current = s.id; });
|
||
navLinks.forEach(l => {
|
||
l.classList.remove('active');
|
||
if (l.getAttribute('href') === '#' + current) l.classList.add('active');
|
||
});
|
||
}, { passive: true });
|
||
</script>
|
||
</body>
|
||
</html>
|